GlaxoSmithKline and the German biotech firm CureVac sign an agreement worth 150 million euros ($180.7 million) to develop a vaccine to counter many variants of SARS-CoV-2. The vaccine, which is subject to regulatory approval, is expected to be introduced in 2022.
GlaxoSmithKline and German biotech firm CureVac sign an agreement worth 150 million euros ($180.7 million) to develop a vaccine to counter many variants of SARS-CoV-2, with target to be introduced in 2022, subject to regulatory approval.
GlaxoSmithKline and theGerman biotech firm CureVac sign an agreement worth 150 million euros ($180.7 million) to develop a vaccine to counter many variants of SARS-CoV-2.Thevaccine,which is subject to regulatory approval,isexpectedtobeintroducedin2022.
